Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, has announced a comprehensive suite of end-to-end solutions for pain therapeutic development. The platform includes diverse validated in vivo pain models and a complete range of preclinical research capabilities, designed to meet the complex demands of modern pain drug research. According to the company, the services cover every stage from early target discovery and mechanism verification through pharmacological validation and safety assessment.
Ace Therapeutics builds integrated in vitro and in vivo research platforms tailored to study various physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates. A core strength of the offering is its extensive portfolio of standardized and customized in vivo pain models for drug testing, which span nearly all mainstream pain classifications. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as multiple neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services, including mechanical, thermal, chemical, cold, and electrical stimulation pain assessments using well-established testing methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Meanwhile, the in vitro neuropathic pain model development services leverage dorsal root ganglion cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, enhancing translational value.
Beyond model construction and efficacy testing, the preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These services support research targeting G-protein coupled receptors, cytokine networks, and various ion channels, delivering professional solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. The platform also offers mechanism-driven research covering peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline includes target validation, in vitro screening, in vivo pharmacology research, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection for analgesic drugs. For special research needs, Ace Therapeutics can also design customized pain models and testing assays according to unique drug mechanisms and research objectives.
This announcement is significant as it provides a one-stop solution for pharmaceutical and biotech companies developing novel pain treatments, potentially streamlining the early-stage research process and addressing the critical need for effective pain management therapies.
